Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06611891 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

Study acronym: DOTABREAST
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 4, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description revised
    • Site contact updated
    • Publications: details revised at 5 of 9 entries
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2024 to Jan 6, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
DOTABREAST: Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer This is a prospective, monocentric, non-controlled, non-randomized, open-label, interventional study.
Trial Details
NCT Number NCT06611891
Lead Sponsor University Hospital, Grenoble
Conditions
(from sponsor)		 Breast Cancer Metastatic
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov